One Bone Lesion Before Myeloma: Solitary Plasmacytoma
One bone lesion. A biopsy that names plasma cells. A marrow that comes back clean. On paper that is a diagnosis. In practice it is a statement about absence, and an absence is only worth as much as the search that went looking. Holding that whole search as one case, rather than as a run of separate results, is the problem Healz was built around.
What follows is what the diagnosis requires, which tests do the ruling out, and why the follow-up runs for years.
What the diagnosis actually claims
A European Expert Panel review puts the cumulative incidence at 0.15 per 100,000, while US registry series report rates two to three times that, so treat the figure as an order of magnitude rather than a rate (Caers et al., Journal of Hematology and Oncology, 2018). In the single-centre series that review cites, 1,272 patients had multiple myeloma, 60 had solitary bone plasmacytoma and 22 had extramedullary plasmacytoma.
The IMWG criteria (Rajkumar et al., Lancet Oncology, 2014) set four requirements, and all four have to be met at once: a biopsy-proven solitary lesion of bone or soft tissue with evidence of clonal plasma cells; a normal bone marrow with no evidence of clonal plasma cells; a normal skeletal survey and MRI, or CT, of the spine and pelvis apart from that one lesion; and absence of end-organ damage such as hypercalcaemia, renal insufficiency, anaemia or bone lesions that can be attributed to a lymphoplasma cell proliferative disorder. IMWG also names a separate category, solitary plasmacytoma with minimal marrow involvement, where the same requirements hold but clonal bone marrow plasma cells are under 10%.
Ask Healz.
One chat instead of ten apps. 1M+ rare cases checked. The root cause, not the label. Private.
Only one of those criteria is positive: the lesion was biopsied and the cells are clonal. The European panel is specific that monoclonality has to be demonstrated, "by kappa/lambda light chain restriction or by a PCR-based approach", so a pathology report naming plasma cells has not finished the job until it establishes the clone. The other three are negatives. As the panel puts it, "since SP is defined by the absence of other bone or extramedullary lesions, imaging is required to exclude a MM diagnosis".
Why a bone lesion and a soft-tissue one behave differently
Solitary bone plasmacytoma "is defined by the presence of a single lytic lesion due to monoclonal PC infiltration, with or without soft-tissue extension". Extramedullary plasmacytoma "consists of a soft-tissue mass that is not in contact with bone" (Caers et al., 2018). Contact with bone is the dividing line, not the presence of soft tissue.
Bone accounts for most cases, roughly 70% of solitary plasmacytoma, and it favours the bones that still hold red marrow: the vertebrae, the femurs, the pelvis and the ribs. The extramedullary form turns up most often in the head and neck, the sinuses and the naso- and oropharynx, and in the gastrointestinal tract and lungs.
Over ten years the European panel's own figures span a range: its background text reports that approximately 50% of patients with solitary bone plasmacytoma and 30% with extramedullary plasmacytoma develop myeloma within 10 years, while its prognostic table puts bone progression at 65% to 84% and extramedullary at 25% to 35% at the same mark (Caers et al., 2018). Read the bone figure as about half or more, not as a forecast. The panel also recommends PET-CT specifically in extramedullary disease, to find soft-tissue lesions a bone-focused search is not aimed at.
Myeloma is where a share of these cases arrive, and its early symptoms tend to be unremarkable taken one at a time, as covered in our piece on the vague symptoms that turn out to be multiple myeloma.
The workup that decides the answer
The lesion itself is biopsied, and the pathology has to establish clonality rather than simply describe plasma cells. Then the marrow: "A unilateral BM aspiration and trephine biopsy is recommended for all patients with suspected SP" (Caers et al., 2018). Both samples, because the pair is what allows plasma cell morphology and total infiltration to be assessed. What that tissue is read for, and why the two samples answer different questions, sits in our guide to what a bone marrow biopsy report says.
The protein studies run in parallel: serum and urine electrophoresis with immunofixation, plus serum free light chains. The panel calls monitoring of serum electrophoresis and immunofixation after treatment completion mandatory, and says an abnormal serum free light chain ratio at diagnosis belongs in the initial assessment because it carries prognostic information. The NCI's PDQ summary notes that about 25% of patients with isolated plasmacytoma of bone have M protein detectable in serum or urine, and that it generally disappears after adequate radiation to the lesion.
Then the imaging, which is where the diagnosis is most often made or unmade. A plain skeletal survey is not enough on its own: the panel states that skeletal surveys "are not sensitive enough to detect early lytic bone lesions", and the NCI summary notes that MRI may reveal unsuspected bony lesions undetected on standard radiographs. So in addition to the skeletal survey or CT, the panel treats MRI or PET-CT as needed to exclude additional lesions, and at least one of them as mandatory.
PET-CT may show additional lesions with therapeutic implications in 33% to 55% of patients with a presumed solitary bone plasmacytoma (Caers et al., 2018). That is not a refinement of the diagnosis. It is a different diagnosis, with a different treatment.
When the marrow is not quite clean
Minimal marrow infiltration by clonal plasma cells, below 10%, "was still considered consistent with a SP diagnosis". The IMWG 2014 table carries a footnote that a solitary plasmacytoma with 10% or more clonal plasma cells is regarded as multiple myeloma, which is why the threshold is a reclassification rather than a grade.
The trace is not cosmetic. "At diagnosis, the presence of minimal BM infiltration by clonal PCs is a strong prognostic factor" (Caers et al., 2018). IMWG puts progression to myeloma within three years at about 10% for a solitary plasmacytoma, against 60% for a bone lesion with minimal marrow involvement and 20% for an extramedullary one (Rajkumar et al., 2014, reproduced in Caers et al., 2018). A trace of clone in the marrow moves the case by six times at three years.
Flow cytometry of the marrow sharpens the same picture. In the data the panel reports, 71% of patients with solitary bone plasmacytoma and positive marrow flow cytometry went on to myeloma, against 8% of those with negative flow, with a median time to progression of 26 months in the positive group.
What treatment is, and why the watching lasts years
"Radiation therapy is the standard treatment for SBP and EMP", and the panel's recommendation is a total fractionated dose of 40 to 50 Gy, with a margin of at least 2 cm (Grade 1A). The NCI's summary likewise describes radiation directed at the lesion as the treatment for isolated plasmacytoma of bone, and notes that myeloma is potentially curable when it presents this way. It also notes that most patients eventually develop disseminated disease, almost 50% of them within two years of diagnosis, which is why the surveillance starts immediately rather than at year five.
So the active treatment is short and local, and then the case does not close. The follow-up has a job: the electrophoresis, the immunofixation and the free light chains keep being repeated long after the radiation field has cooled, because a rising paraprotein is how progression announces itself before symptoms do.
How Healz reads a diagnosis built on absence
The marrow report, the protein electrophoresis and the whole-body imaging only mean anything read against each other. They ordinarily arrive one letter at a time, weeks apart, each from a different department. Healz holds them in one chat, not ten apps and three portals.
Healz is equipped with Frontier AI, so the case is worked whole: the clonality statement on the lesion biopsy read against the marrow percentage, and the imaging read for what it was ordered to exclude rather than only for what it found.
Healz is equipped with root-cause technology, so it does not stop at the first label. Solitary is a claim, and the questions a rushed appointment skips are the ones that test it: whether the marrow had both an aspirate and a trephine, whether flow cytometry was run on it, whether anything looked past the plain films. It cross-checks the case against more than a million rare cases, so a presentation that does not quite fit stays open instead of closing on the first word in the report.
Healz's memory pulls the medical facts out of every upload, keeps abnormal values up front, dates each finding and connects them across months, so a paraprotein level from before radiation sits next to the one drawn a year later instead of in two separate portals. A cancer ai that reads a pathology report against the rest of the file turns a second opinion into a question about the whole case. You can bring a board-certified doctor into the same chat for a second opinion.
Frequently asked questions
- What is a solitary plasmacytoma?
It is a single tumour of clonal plasma cells, in bone or in soft tissue, in someone whose marrow and rest of the skeleton look clear. The IMWG criteria require a biopsy-proven lesion with clonal plasma cells; a normal bone marrow with no evidence of clonal plasma cells; a normal skeletal survey and MRI, or CT, of the spine and pelvis apart from that one lesion; and absence of end-organ damage such as hypercalcaemia, renal insufficiency, anaemia or bone lesions attributable to a lymphoplasma cell proliferative disorder.
- Does solitary plasmacytoma always turn into multiple myeloma?
No, but a meaningful share of cases do, and that is what the long follow-up is for. The European Expert Panel's own figures span a range at ten years: its background text reports that approximately 50% of patients with solitary bone plasmacytoma and 30% with extramedullary plasmacytoma develop myeloma within 10 years, while its prognostic table puts bone progression at 65% to 84% and extramedullary at 25% to 35% at the same mark (Caers et al., Journal of Hematology and Oncology, 2018). Read the bone figure as about half or more, not as a forecast.
- Why order a PET-CT or MRI when the X-rays were clear?
Because a skeletal survey misses lesions that change the diagnosis. The European panel states that skeletal surveys are not sensitive enough to detect early lytic bone lesions, and reports that PET-CT shows additional lesions with therapeutic implications in 33% to 55% of patients with a presumed solitary bone plasmacytoma. It treats at least one of MRI or PET-CT as mandatory for that reason.
- What does minimal marrow involvement mean on a plasmacytoma report?
It means clonal plasma cells were found in the marrow but made up less than 10% of it, which still fits a solitary plasmacytoma diagnosis under the IMWG framework. At 10% or more the case is classed as multiple myeloma instead. The panel describes minimal involvement as a strong prognostic factor, with a markedly higher three-year progression rate than a marrow with no clone at all.
One lesion, a clean marrow and a clear film still add up to a diagnosis about absence, and an absence is worth exactly as much as the search that went looking for something else.
Written by Healz Team · Filed under Health Insights
